Retinal stem cell compositions and methods for preparing and using same

• US 20080089868A1
• Filed: 04/27/2007
• Published: 04/17/2008
• Est. Priority Date: 04/27/2006
• Status: Abandoned Application

• Current Assignee: The Research Foundation for The State University of New York (State University of New York)
• Original Assignee: The Research Foundation for The State University of New York (State University of New York)
• Inventors: Zuber, Michael, Viczian, Andrea
• Application Number:
  US11/796,171
• Publication Number:
  US 20080089868A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/60 Transcription factors
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0623 Stem cells
• CPC Class Codes: C12N 5/0687 Renal stem cells; Renal progenitors

Abstract

Provided are cell compositions including non-retinal cell types that have been reprogrammed to form retinal stem cells, and methods for producing and using same. Such reprogrammed cells can be used to replace one or more retinal cell types that have been lost due to damage and/or disease and are thus useful in treating or preventing visual impairment.

Claims

1. A composition comprising a population of retinal stem cells, said retinal stem cells comprising a population of reprogrammed non-retinal cells.

2. The composition of claim 1, wherein the population of retinal stem cells is mammalian.

3. The composition of claim 2, wherein said mammalian retinal stem cells are human.

4. The composition of claim 1, wherein said retinal stem cells are capable of producing retinal progenitor cells, retinal cells, and adult retinal stem cells.

5. The composition of claim 4, wherein said retinal cells are selected from one or more of the following:

(a) rod cells;

(b) cone cells;

(c) bipolar cells;

(d) amacrine cells;

(e) retinal ganglion cells;

(f) retinal pigment epithelial cells;

(g) Mueller cells; and

(h) horizontal cells.

6. The composition of claim 1, wherein the non-retinal cells are selected from ectodermal cells.

7. The composition of claim 6, wherein said ectodermal cells are epidermal stem cells.

8. The composition of claim 7, wherein said epidermal stem cells are reprogrammed embryonic stem cells or cells harvested from a patient'"'"'s skin, or a combination thereof.

9. The composition of claim 1, wherein the non-retinal cell types are reprogrammed with a gene set comprising an eye-field transcription factor cocktail.

10. The composition of claim 9, wherein the eye-field transcription factor cocktail comprises nucleic acid sequences encoding the following:

Otx2;

ET;

Rx1;

Pax6;

Six3;

tll;

Optx2; and

orthologs thereof.

11. The composition of claim 1, wherein the non-retinal cell types are reprogrammed by externally applying or causing the cells to express or over express one or more secreted activator or inhibitor of a signaling pathway involved in retinal stem cell formation.

12. The composition of claim 11, wherein said signaling pathway is selected from one or more of the following:

(a) hedgehog (Hh);

wingless (Wnt);

transforming growth factor-β

(TGF-β

);

bone morphogenic protein (BMP);

insulin growth factor (IGF); and

fibroblast growth factor (FGF).

13. The composition of claim 11, wherein said activator or inhibitor is an antagonist of BMP.

14. The composition of claim 13, wherein said antagonist of BMP is selected from one or more of the following:

(a) fetuin;

(b) noggin;

(c) chordin;

(d) gremlin;

(e) follistatin;

(f) cerberus;

(g) amnionless;

(h) DAN; and

(i) the ecto domain of the BMP receptor protein BMRIA.

15. The composition of claim 14, wherein said antagonist of BMP is noggin.

16. The composition of claim 12, wherein the signaling pathway is TGF-β

and the secreted molecule is nodal.

25. A pharmaceutical composition comprising a therapeutically effective amount of the composition according to claim 1 and a pharmaceutically acceptable diluent, excipient, or carrier.

28. A method of treating or preventing visual impairment, the method comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 25 to a subject in need thereof.

29. The method of claim 28, wherein said visual impairment is caused by one or more of the following:

(a) glaucoma;

(b) retinitis pigmentosa;

(c) age-related macular degeneration;

(d) diabetic retinopathy; and

(e) retinal injuries.

30. The method of claim 28, wherein the administering step is performed by injection or implantation.

31. The method of claim 30, wherein the injection is intravitreally.

17. A composition comprising a population of non-retinal cell types that have been genetically altered to express or over-express a gene set comprising an eye-field transcription factor cocktail.

18. The composition of claim 17, wherein the eye-field transcription factor cocktail comprises nucleic acid sequences encoding the following:

Otx2;

ET;

Rx1;

Pax6;

Six3;

tll;

Optx2;

or orthologs thereof.

26. A pharmaceutical composition comprising a therapeutically effective amount of the composition according to claim 17 and a pharmaceutically acceptable diluent, excipient, or carrier.

19. A composition comprising a population of non-retinal cell types that have been externally treated with one or more secreted activator or inhibitor of a signaling pathway involved in retinal stem cell formation.

20. The composition of claim 19, wherein said signaling pathway is selected from one or more of the following:

(a) hedgehog (Hh);

wingless (Wnt);

transforming growth factor-β

(TGF-β

);

bone morphogenic protein (BMP);

insulin growth factor (IGF); and

fibroblast growth factor (FGF).

21. The composition of claim 19, wherein said activator or inhibitor is an antagonist of BMP.

22. The composition of claim 21, wherein said antagonist of BMP is selected from one or more of the following:

(a) fetuin;

(b) noggin;

(c) chordin;

(d) gremlin;

(e) follistatin;

(f) Cerberus;

(g) amnionless;

(h) DAN; and

(i) the ecto domain of the BMP receptor protein BMRIA.

23. The composition of claim 22, wherein said antagonist of BMP is noggin.

24. The composition of claim 20, wherein the signaling pathway is TGF-β

and the secreted molecule is nodal.

27. A pharmaceutical composition comprising a therapeutically effective amount of the composition according to claim 19 and a pharmaceutically acceptable diluent, excipient, or carrier.

32. A method of reprogramming a population of non-retinal cells, the method comprising:

(a) providing a cell population comprising one or more non-retinal cell types; and

(b) genetically altering the cells to express or over express a gene set comprising an eye-field transcription factor cocktail,

thereby reprogramming said non-retinal cells to retinal stem cells.

33. A method of claim 32, wherein the non-retinal cells types are ectodermal cells.

34. The method of claim 33, wherein the ectodermal cells are epidermal stem cells.

35. A method of claim 32, wherein the eye-field transcription factor cocktail comprises nucleic acid sequences encoding the following:

Otx2;

ET;

Rx1;

Pax6;

Six3;

tll;

Optx2; and

orthologues thereof.

36. A method of reprogramming a population of non-retinal cells, the method comprising:

a. providing a cell population comprising one or more non-retinal cell types; and

b. exposing said cells to one or more secreted activator or inhibitor of a signaling pathway involved in retinal stem cell formation.

thereby reprogramming the non-retinal cells to retinal stem cells.

37. The method of claim 36, wherein said non-retinal cells are ectodermal cells.

38. The method of claim 37, wherein the ectodermal cells are epidermal stem cells.

39. The composition of claim 36, wherein said signaling pathway is selected from one or more of the following:

(a) hedgehog (Hh);

wingless (Wnt);

transforming growth factor-β

(TGF-β

);

bone morphogenic protein (BMP);

insulin growth factor (IGF); and

fibroblast growth factor (FGF).

40. A method of claim 36, wherein said secreted activator or inhibitor of the signaling pathway(s) involved in retinal stem cell formation is an antagonist of BMP.

41. A method of claim 40, wherein said antagonist of BMP is selected from one or more of the following:

(a) fetuin;

(b) noggin;

(c) chordin;

(d) gremlin;

(e) follistatin;

(f) Cerberus;

(g) amnionless;

(h) DAN; and

(i) the ecto domain of the BMP receptor protein BMRIA.

42. A method of claim 41, wherein said antagonist of BMP is noggin.

43. The composition of claim 39, wherein the signaling pathway is TGF-β

and the secreted molecule of TGF-β

is nodal.

44. A method of reprogramming embryonic stem cells comprising:

(a) providing a cell population of embryonic stem cells;

(b) exposing the embryonic stem cells to factors causing them to differentiate into primitive ectodermal cells; and

(c) exposing the primitive ectodermal cells to one or more secreted activator and inhibitor of a signaling pathway involved in retinal stem cell formation,

thereby reprogramming said embryonic stem cells to retinal stem cells.

45. The composition of claim 44, wherein said signaling pathway is selected from one or more of the following:

(a) hedgehog (Hh);

wingless (Wnt);

transforming growth factor-β

(TGF-β

);

bone morphogenic protein (BMP);

insulin growth factor (IGF); and

fibroblast growth factor (FGF).

46. A method of claim 44, wherein said secreted activator or inhibitor of the signaling pathway involved in retinal stem cell formation is an antagonist of BMP.

47. A method of claim 46, wherein said antagonist of BMP is selected from one or more of the following:

(a) fetuin;

(b) noggin;

(c) chordin;

(d) gremlin;

(e) follistatin;

(f) Cerberus;

(g) amnionless;

(h) DAN; and

(i) the ecto domain of the BMP receptor protein BMRIA.

48. A method of repopulating one or more retinal cell types, the method comprising:

(a) providing a cell population comprising one or more non-retinal cell types;

(b) exposing the cells to one or more secreted activator or inhibitor of a signaling pathway involved in retinal stem cell formation, thereby reprogramming the non-retinal cells to retinal stem cells; and

(c) injecting the retinal stem cells of step (b) into the retina of a subject in need thereof,

whereby the retinal stem cells differentiate into one or more retinal cell types thereby repopulating one or more retinal cell types that have been damaged or diseased.